Pituitary

, Volume 12, Issue 3, pp 280–283

Cushing’s syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma

  • R. A. Alwani
  • S. J. C. M. M. Neggers
  • M. van der Klift
  • M. G. A. Baggen
  • G. J. L. H. van Leenders
  • M. O. van Aken
  • A. J. van der Lely
  • W. W. de Herder
  • R. A. Feelders
Case Report

Abstract

Ectopic adrenocorticotropin (ACTH) secretion accounts for less than 10% of all causes of endogenous Cushing’s syndrome (CS) and is usually associated with neuroendocrine tumors and small cell carcinoma of the lung. We report the case of a 62-year-old man with CS due to ectopic ACTH production by small cell carcinoma of the prostate. He presented with severe hypercortisolism and associated symptoms. Plasma neuron specific enolase (NSE) was grossly elevated. Despite performing a laparoscopic bilateral adrenalectomy, the patient died as a result of sepsis with multi-organ failure. Post-mortem immunohistochemical staining of prostate tumor tissue showed ACTH expression. ACTH staining was also performed in four additional patients with small cell carcinoma of the urinary tract without CS. None of these additional cases showed a positive staining for ACTH. Although a rare cause of ectopic ACTH production, neuroendocrine prostate carcinoma should be considered in male patients with Cushing’s syndrome, in particular in those with an occult source of ACTH overproduction.

Keywords

Ectopic ACTH Cushing’s syndrome Neuroendocrine differentiation Prostate cancer ACTH staining 

References

  1. 1.
    Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK (2005) Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab 90:4955–4962 Medline. doi:10.1210/jc.2004–2527 PubMedCrossRefGoogle Scholar
  2. 2.
    Newell-Price J, Bertagna X. Grossman a B, Nieman LK (2006) Cushing’s syndrome. Lancet 367:1605–1617 Medline. doi:10.1016/S0140-6736(06)68699-6 PubMedCrossRefGoogle Scholar
  3. 3.
    Isidori a M. Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, Jenkins PJ, Monson JP, Grossman a B, Besser GM (2006) The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 91:371–377 Medline. doi:10.1210/jc.2005-1542 CrossRefGoogle Scholar
  4. 4.
    Salgado LR, Fragoso MC, Knoepfelmacher M, Machado MC, Domenice S, Pereira MA, De Mendonca BB (2006) Ectopic ACTH syndrome: our experience with 25 cases. Eur J Endocrinol 155:725–733 Medline. doi:10.1530/eje.1.02278 PubMedCrossRefGoogle Scholar
  5. 5.
    Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture Eur J Cancer 37(Suppl 8):S4–S66 Medline. doi:10.1016/S0959-8049(01)00267-2 Google Scholar
  6. 6.
    Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52:23–47 Medline.Google Scholar
  7. 7.
    Abrahamsson PA (1999) Neuroendocrine differentiation in prostatic carcinoma. Prostate 39:135–148 Medline. doi:10.1002/(SICI)1097-0045(19990501)39:2 < 135::AID-PROS9 > 3.0.CO;2-S PubMedCrossRefGoogle Scholar
  8. 8.
    Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488–1490 Medline. doi:10.1056/NEJMp048178 PubMedCrossRefGoogle Scholar
  9. 9.
    Di Sant’agnese PA (1995) Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer (Suppl) 75:1850–1859Google Scholar
  10. 10.
    Mosca A, Berruti A, Russo L, Torta M, Dogliotti L (2005) The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 28:141–145 MedlineGoogle Scholar
  11. 11.
    Shariff a H, Ather MH (2006) Neuroendocrine differentiation in prostate cancer. Urology 68:2–8PubMedCrossRefGoogle Scholar
  12. 12.
    Taplin ME, George DJ, Halabi S et al (2005) Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in cancer and leukemia group B 9480 study. Urology 66:386–391 Medline. doi:10.1016/j.urology.2005.03.040 PubMedCrossRefGoogle Scholar
  13. 13.
    Vashchenko N, Abrahamsson PA (2005) Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47:147–155 Medline. doi:10.1016/j.eururo.2004.09.007 PubMedCrossRefGoogle Scholar
  14. 14.
    Fjellestad-Paulsen A, Abrahamsson PA, Bjartell A et al (1988) Carcinoma of the prostate with Cushing’s syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue. Acta Endocrinol (Copenh) 119:506–516 MedlineGoogle Scholar
  15. 15.
    Haukaas SA, Halvorsen OJ, Nygaard SJ, Paus E (1999) Cushing’s syndrome in prostate cancer. An aggressive course of prostatic malignancy. Urol Int 63:126–129 Medline. doi:10.1159/000030431 PubMedCrossRefGoogle Scholar
  16. 16.
    Hussein WI, Kowalyk S, Hoogwerf BJ (2002) Ectopic adrenocorticotropic hormone syndrome caused by metastatic carcinoma of the prostate: therapeutic response to ketoconazole. Endocr Pract 8:381–384 MedlineGoogle Scholar
  17. 17.
    Lovern WJ, Fariss BL, Wettlaufer JN, Hane S (1975) Ectopic ACTH production in disseminated prostatic adenocarcinoma. Urology 5:817–820 Medline. doi:10.1016/0090-4295(75)90365-9 PubMedCrossRefGoogle Scholar
  18. 18.
    Newmark SR, Dluhy RG, Bennett a H (1973) Ectopic adrenocorticotropin syndrome with prostatic carcinoma. Urology 2:666–668 Medline. doi:10.1016/0090-4295(73)90333-6 PubMedCrossRefGoogle Scholar
  19. 19.
    Rickman T, Garmany R, Doherty T, Benson D, Okusa MD (2001) Hypokalemia, metabolic alkalosis, and hypertension: Cushing’s syndrome in a patient with metastatic prostate adenocarcinoma. Am J Kidney Dis 37:838–846 MedlineGoogle Scholar
  20. 20.
    Pivonello R, Ferone D, Lamberts SW, Colao A (2005) Cabergoline plus lanreotide for ectopic Cushing’s syndrome. N Engl J Med 352:2457–2458 Medline. doi:10.1056/NEJM200506093522322 PubMedCrossRefGoogle Scholar
  21. 21.
    Francia G, Davi MV, Montresor E, Colato C, Ferdeghini M, Lo Cascio V (2006) Long-term quiescence of ectopic Cushing’s syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine? J Endocrinol Invest 29:358–362 MedlinePubMedGoogle Scholar
  22. 22.
    Chu JW, Matthias DF, Belanoff J, Schatzberg A. Hoffman a R, Feldman D (2001) Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86:3568–3573 Medline. doi:10.1210/jc.86.8.3568 PubMedCrossRefGoogle Scholar
  23. 23.
    Nieman LK, Chrousos GP, Kellner C et al (1985) Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 61:536–540 MedlinePubMedCrossRefGoogle Scholar
  24. 24.
    Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Monaco F, Di Silverio F (2006) New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract 60:462–470 Medline. doi:10.1111/j.1742-1241.2006.00750.x PubMedCrossRefGoogle Scholar
  25. 25.
    Fixemer T, Remberger K, Bonkhoff H (2002) Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 53:118–123 Medline. doi:10.1002/pros.10133 PubMedCrossRefGoogle Scholar
  26. 26.
    Stewart PM, Gibson S, Crosby SR et al (1994) ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol (Oxf) 40:199–204 MedlineCrossRefGoogle Scholar
  27. 27.
    Coates PJ, Doniach I, Howlett TA, Rees LH, Besser GM (1986) Immunocytochemical study of 18 tumours causing ectopic Cushing’s syndrome. J Clin Pathol 39:955–960 Medline. doi:10.1136/jcp.39.9.955 PubMedCrossRefGoogle Scholar
  28. 28.
    Delisle L, Boyer MJ, Warr D et al (1993) Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications Arch Intern Med 153:746–752 Medline. doi:10.1001/archinte.153.6.746 Google Scholar
  29. 29.
    Gewirtz G, Yalow RS (1974) Ectopic ACTH production in carcinoma of the lung. J Clin Invest 53:1022–1032 MedlinePubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • R. A. Alwani
    • 1
    • 4
  • S. J. C. M. M. Neggers
    • 1
  • M. van der Klift
    • 2
  • M. G. A. Baggen
    • 2
  • G. J. L. H. van Leenders
    • 3
  • M. O. van Aken
    • 1
  • A. J. van der Lely
    • 1
  • W. W. de Herder
    • 1
  • R. A. Feelders
    • 1
  1. 1.Department of Internal MedicineEndocrine SectionRotterdamThe Netherlands
  2. 2.Department of Internal MedicineIkazia HospitalRotterdamThe Netherlands
  3. 3.Department of PathologyErasmus Medical CentreRotterdamThe Netherlands
  4. 4.Department of Internal MedicineErasmus Medical CentreRotterdamThe Netherlands

Personalised recommendations